NCT06055894
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) No drug interventions prevention Not Available recruiting NCT00099047
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma prevention 2 completed NCT05597345
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma treatment 2 recruiting NCT05469893
Immuno-PRISM (PRecision Intervention Smoldering Myeloma) treatment 2 recruiting NCT02916771
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma treatment 2 active_not_recruiting NCT03289299
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant treatment 2 active_not_recruiting NCT02415413
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma treatment 2 active_not_recruiting NCT00503763
Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma treatment 2 withdrawn NCT01222286
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma treatment 2 completed NCT01302886
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma No drug interventions treatment 2 completed NCT03850522
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma No drug interventions treatment 2 terminated NCT02886065
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM prevention 1 active_not_recruiting NCT03301220
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma treatment 3 active_not_recruiting NCT01441973
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma treatment 2 completed NCT01177527
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders No drug interventions Not Available Not Available active_not_recruiting NCT06365060
Screening for AL Amyloidosis in Smoldering Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT02279394
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma treatment 2 completed NCT03717844
Registry for Adults With Plasma Cell Disorders (PCD's) No drug interventions Not Available Not Available recruiting NCT00114101
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant No drug interventions treatment 3 active_not_recruiting NCT04615572
Screening to Improve Survival in AL Amyloidosis No drug interventions Not Available Not Available completed NCT04850846
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma No drug interventions treatment 2 active_not_recruiting NCT01955395
Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma No drug interventions supportive_care Not Available completed NCT05841550
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma No drug interventions treatment 1 / 2 recruiting NCT06212323
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial No drug interventions Not Available Not Available recruiting NCT06383143
Promoting Diagnosis and Management of AL in Italy (ProDigALIty) No drug interventions Not Available Not Available recruiting NCT06237803
European Myeloma Network (EMN) Sample Project No drug interventions Not Available Not Available recruiting NCT04920084
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) No drug interventions prevention Not Available active_not_recruiting NCT03815279
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) No drug interventions treatment 2 enrolling_by_invitation NCT04144387
Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. No drug interventions screening Not Available active_not_recruiting NCT01237054
Imaging in MGUS, SMM and MM No drug interventions diagnostic 2 completed NCT00899353
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) No drug interventions treatment 2 terminated NCT03236428
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma No drug interventions treatment 2 active_not_recruiting NCT05283993
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH No drug interventions Not Available Not Available recruiting NCT06472778
A Real-world Study in Participants With Smoldering Multiple Myeloma No drug interventions Not Available Not Available recruiting NCT01169337
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma No drug interventions treatment 3 active_not_recruiting NCT03839459
Denosumab for Smoldering Multiple Myeloma No drug interventions treatment 2 active_not_recruiting NCT05767359
CAR- PRISM (PRecision Intervention Smoldering Myeloma) No drug interventions treatment 2 recruiting NCT01718899
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma No drug interventions treatment 1 completed NCT05831358
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program No drug interventions screening Not Available recruiting NCT01571726
Imaging Studies and the Development of Multiple Myeloma No drug interventions diagnostic 2 withdrawn NCT00112827
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma No drug interventions treatment 1 / 2 completed NCT05361694
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions No drug interventions Not Available Not Available recruiting NCT04727294
MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey No drug interventions Not Available Not Available unknown_status NCT06183489
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma No drug interventions treatment 2 recruiting NCT02269592
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome No drug interventions Not Available Not Available recruiting NCT01838369
A Phase II Study of BI-505 in Smoldering Multiple Myeloma No drug interventions treatment 2 terminated NCT02903381
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma No drug interventions treatment 2 completed NCT01248455
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma No drug interventions treatment 2 terminated NCT00919139
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. No drug interventions Not Available Not Available completed NCT01079429
Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. No drug interventions Not Available Not Available terminated NCT01109407
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) No drug interventions Not Available Not Available terminated NCT03591614
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma No drug interventions treatment 0 withdrawn NCT05955508
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma No drug interventions treatment 2 recruiting NCT02240537
Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer No drug interventions treatment 1 unknown_status NCT06140524
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma No drug interventions treatment 2 recruiting NCT04731844
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer No drug interventions treatment 2 recruiting NCT04370483
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma treatment 0 active_not_recruiting NCT04776395
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma No drug interventions treatment 2 recruiting NCT02726750
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma No drug interventions Not Available Not Available recruiting NCT02492750
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma No drug interventions treatment 1 completed NCT03631043
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma No drug interventions treatment 0 active_not_recruiting NCT02603887
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma No drug interventions treatment 0 active_not_recruiting NCT05136807
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies No drug interventions Not Available Not Available recruiting NCT03952832
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma No drug interventions treatment 2 withdrawn NCT03937635
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma No drug interventions treatment 3 recruiting NCT05288062
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma No drug interventions treatment 2 active_not_recruiting NCT02353572
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma No drug interventions treatment 1 / 2 terminated NCT05014646
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients No drug interventions prevention 2 recruiting NCT02960555
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) No drug interventions treatment 2 active_not_recruiting NCT05312255
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma No drug interventions treatment Not Available recruiting